Enrollment Complete in Phase 2 Trial Testing Temelimab

Enrollment Complete in Phase 2 Trial Testing Temelimab

287687

Enrollment Complete in Phase 2 Trial Testing Temelimab

GeNeuro has completed patient enrollment in its ProTEct-MS Phase 2 clinical trial evaluating temelimab as a treatment for multiple sclerosis (MS), the company announced. The study (NCT04480307), taking place at the Karolinska Institutet’s Academic Specialist Center (ASC) in Stockholm, Sweden, has enrolled 42 people with relapsing MS whose disability progressed in the absence of relapses after treatment with rituximab. Top-line results are expected by March 2022. “MS disease progression continues to be a major unmet need…

You must be logged in to read/download the full post.